Clinical trial
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations…
NCT00958438 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00958438 |
|---|---|
| Title | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gout |
| Intervention type | Drug |
| Interventions | Placebo, Rilonacept |
| Enrollment | 248 |
| Start date | Jul 1, 2009 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Aug 13, 2009 |
| Last update posted | Apr 28, 2017 |
| Countries | Germany, India, Indonesia, South Africa, Taiwan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: